KLF4 and neoplasm: Accordingly, our in vivo xenograft studies demonstrated that with KLF4 overexpression, EpCAM−/CD133− non-stem cells attained an in vivo tumor-forming ability comparable to EpCAM+/CD133+ LCSCs.